ADBiotech Co

ADBiotech Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of ADBiotech Co (179530.KQ) as of Nov 22, 2026 is -10.14. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -4.71 — a change of 115.12% (lower).

EV/EBITDA

-10.14

YoY

115.12%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of ADBiotech Co is 2025 -10.14 . EV/EBITDA (Enterprise Value to EBITDA) of ADBiotech Co was 2024 -4.71 . It decreases by 115.12% lower compared to the previous year.

The ADBiotech Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-10.66 KRW
Jan 1, 2019
119.72 KRW
Jan 1, 2020
-39.02 KRW
Jan 1, 2021
-16.53 KRW
Jan 1, 2022
-6.53 KRW
Jan 1, 2023
-4.46 KRW
Jan 1, 2024
-4.71 KRW
Jan 1, 2025
-10.14 KRW
The ADBiotech Co EV/EBITDA history
YEAREV/EBITDAYoY
-10.14+115.12%
-4.71+5.71%
-4.46-31.74%
-6.53-60.47%
-16.53-57.65%
-39.02-132.60%
119.72-1,222.53%
-10.66-113.74%
77.65-329.63%
-33.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ADBiotech Co Stock analysis

What does ADBiotech Co do? ADbiotech Co., Ltd. generates revenue by manufacturing and selling chemical products across two distinct business segments. The Veterinary Medicine segment focuses on the production of antibiotics, anticoccidial agents, antimicrobial agents, nervous system agents, and synthetic antibacterial agents for use in pharmaceuticals and stockbreeding. This division serves customers in the animal health sector by providing essential medical compounds for livestock and other animals. The Supplementary Feed segment complements the core operations by manufacturing and selling functional supplementary feeds and other related products. This segment targets the stockbreeding and fisheries industries, offering nutritional solutions to enhance animal health and productivity. By combining these two segments, ADBiotech Co., Ltd. delivers a comprehensive range of chemical and feed-based solutions to its clients in Chuncheon, Gangwon-Do. ADBiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADBiotech Co stock

EV/EBITDA (Enterprise Value to EBITDA) of ADBiotech Co is -10.14 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of ADBiotech Co changed from -4.71 to -10.14, representing a 115.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) ADBiotech Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s ADBiotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ADBiotech Co

All Key Metrics — ADBiotech Co